Oxidative stress in blood in Alzheimer's disease and mild cognitive impairment: A meta-analysis

Neurobiology of Disease

Volumn 59, Issue , 2013, Pages 100-110

  Schrag, M ^a   Mueller, C ^b   Zabel, M ^c   Crofton, A ^c   Kirsch, W M ^c   Ghribi, O ^d   Squitti, R ^e   Perry, G ^f  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGE MASON UNIVERSITY   (United States)

^c LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NORTH DAKOTA   (United States)

^e IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^f UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

Author keywords

Alzheimer's disease; Ceruloplasmin oxidase; Cognitive aging; Copper; Glutathione; Lipid peroxidation; Oxidative stress; Singlet oxygen

Indexed keywords

8 HYDROXYGUANOSINE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; CATALASE; CERULOPLASMIN; COPPER; COPPER ZINC SUPEROXIDE DISMUTASE; EXTRACELLULAR SUPEROXIDE DISMUTASE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GUANOSINE; MALONALDEHYDE; RETINOL; TRANSFERRIN; UNCLASSIFIED DRUG; URIC ACID;

ALZHEIMER DISEASE; ANTIOXIDANT BLOOD LEVEL; ARTICLE; BLOOD LEVEL; CERULOPLASMIN BLOOD LEVEL; COPPER BLOOD LEVEL; COPPER METABOLISM; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; HUMAN; LIPID PEROXIDATION; META ANALYSIS (TOPIC); METABOLIC DISORDER; MILD COGNITIVE IMPAIRMENT; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; QUALITY CONTROL PROCEDURES; RANDOMIZATION; SYSTEMATIC REVIEW; TRANSFERRIN BLOOD LEVEL;

ALZHEIMER'S DISEASE; CERULOPLASMIN OXIDASE; COGNITIVE AGING; COPPER; GLUTATHIONE; LIPID PEROXIDATION; OXIDATIVE STRESS; SINGLET OXYGEN;

ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL MARKERS; CERULOPLASMIN; DATABASES, BIBLIOGRAPHIC; GLUTATHIONE; HUMANS; LIPID PEROXIDATION; MILD COGNITIVE IMPAIRMENT; OXIDATIVE STRESS;

EID: 84881630187     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.07.005     Document Type: Article

References (134)

1. Agarwal R., Kashwaha S., Tripathi C., Singh N., Chhillar N. Serum copper in Alzheimer's disease and vascular dementia. Indian J. Clin. Biochem. 2008, 23:369-374.
2. Ahlskog J., Uitti R.J., Low P.A., Tyce G.M., Nickander K.K., Petersen R.C., Kokmen E. No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease. Mov. Disord. 1995, 10:566-573.
3. Aldred S., Bennett S., Mecocci P. Increased low-density lipoprotein oxidation, but not total plasma protein oxidation in Alzheimer's disease. Clin. Biochem. 2010, 43:267-271.
4. Arnal N., Cristalli D., de Alaniz M., Marra C. Clinical utiliy of copper, ceruloplasmin and metallothionein plasma determinations in human neurodegenerative patients and their first-degree relatives. Brain Res. 2010, 1319:118-130.
5. Aybek H., Ercan F., Aslan D., Sahiner T. Determination of malondialdehyde, reduced glutathione levels and APOE4 allele frequency in late-onset Alzheimer's disease in Denizli, Turkey. Clin. Biochem. 2007, 40:172-176.
6. Baldeiras I., Santana I., Proenca M.T., Garrucho M.H., Pascoal R., Rodrigues A., et al. Peripheral oxidative damage in mild cognitive impairment and mild Alzheimer's disease. J. Alzheimers Dis. 2008, 15:117-128.
7. Battino M., Bompadre S., Leone L., Devecchi E., Degiuli A., D'Agostino F., et al. Coenzyme Q, vitamin E, and apo-E alleles in Alzheimer disease. Biofactors 2003, 18:277-281.
8. Baum L., Chan I.H., Cheung S.K., Goggins W.B., Mok V., Lam L., et al. Serum zinc is decreased in Alzheimer's disease and serum arsenic correlates positively with cognitive ability. Biometals 2010, 23:173-179.
9. Bermejo P., Gomez-Serranillos P., Santos J., Pastor E., Gil P., Martin-Aragon S. Determination of malondialdehyde in Alzheimer's disease: a comparative study of high-performance liquid chromatography and thiobarbituric acid test. Gerontology 1997, 43:218-222.
10. Bermejo P., Martin-Aragon S., Benedi J., et al. Peripheral levels of glutathione and protein oxidation as markers in the development of Alzheimer's disease from mild cognitive impairment. Free Radic. Res. 2008, 42:162-170.
11. Berr C., Balansard B., Arnaud J., Roussel A.M., Alperovitch A. Cognitive decline is associated with systemic oxidative stress: the EVA study. Etude du Vieillissement Arteriel. J. Am. Geriatr. Soc. 2000, 48:1285-1291.
12. Bourdel-Marchasson I., Delmas-Beauvieux M., Peuchant E., Richard-Harston S., Decamps A., et al. Antioxidant defenses and oxidative stress markers in erythrocytes and plasma from normally nourished elderly Alzheimer patients. Age Ageing 2001, 30:235-241.
13. Brewer G., Kanzer S., Zimmerman E., Celmins D., Heckman S., Dick R. Copper and ceruloplasmin abnormalities in Alzheimer's disease. Am. J. Alzheimers Disord. 2010, 25:490-497.
14. Bucossi S., Ventriglia M., Panetta V., et al. Copper in Alzheimer's disease: a meta-analysis of serum, plasma and cerebrospinal fluid studies. Am. J. Alzheimers Disord. 2010, 24:175-185.
15. Bucossi S., Mariani S., Ventriglia M., Plomanti R., Gennarelli M., Bonvicini C., et al. Association between the c.2945 A>G ATP7B polymorphism and sporadic Alzheimer's disease. Int. J. Alzheimers Dis. 2011, 2011:973692.
16. Cai Z., Yan Y., Yan L., Wang F., Huang H., Wang Y., Zhao Y. Serum level of MMP-2, MMP-9 and Ox-LDL in Alzheimer's disease with hyperlipoidemia. J. Med. Coll. PLA 2007, 22:352-356. (ox LDL).
17. Carantoni M., Zuliani G., Munari M., D'Elia K., Pamieri E., Fellin R. Alzheimer disease and vascular dementia: relationships with fasting glucose and insulin levels. Dement. Geriatr. Cogn. Disord. 2000, 11:176-180.
18. Casado A., Encarnacion Lopez-Fernandez M., Concepcion Casado M., de La Torre R. Lipid peroxidation and antioxidant enzyme activities in vascular and Alzheimer dementia. Neurochem. Res. 2008, 33:450-458.
19. Cascalheira J., Joao S., Pinhancos S., Castro R., Palmeira M., Almeida S., et al. Serum homocysteine: interplay with other circulating and genetic factors in association to Alzheimer's type dementia. Clin. Biochem. 2009, 42:783-790.
20. Ceballos-Picot I., Merad-Boudia M., Nicole A., Thevenin M., Hellier G., Legrain S., Berr C. Peripheral antioxidant enzyme activities and selenium in elderly subjects and in dementia of Alzheimer's type - place of the extracellular glutathione peroxidase. Free Radic. Biol. Med. 1996, 20:579-587.
21. Cito A., Porcelli B., Coppola M., Mangiavacchi P., Cortelazzo A., Terzuoli L. Analysis of serum levels of homocysteine and oxidative stress markers in patients with Alzheimer disease. Biomed. Pharmacother. 2013, (in press). 10.1016/j.biopha.2010.09.018.
22. Conrad C.C., Marshall P.L., Talent J.M., Malakowsky C., Choi J., Gracy R. Oxidized proteins in Alzheimer's plasma. Biochem. Biophys. Res. Commun. 2000, 275:678-681.
23. Corrigan F.M., Crichton J.S., Van Rhijn A.G., Skinner E.R., Ward N.I. Transferrin, cholesterol and aluminum in Alzheimer's disease. Clin. Chim. Acta 1992, 211:121-123.
24. Cristalli D.O., Arnal N., Marra F., de Alaniz M., Marra C. Peripheral markers in neurodegenerative patients and their first-degree relatives. J. Neurol. Sci. 2012, 314:48-56.
25. De Leo M.E., Borrello S., Passantino M., Palazzotti B., Mordente A., Daniele A., et al. Oxidative stress and overexpression of manganese superoxide dismutase in patients with Alzheimer's disease. Neurosci. Lett. 1998, 250:173-176.
26. De Lustig E.S., Serra J.A., Kohan S., Canziani G.A., Famulari A., Dominguez R.O. Copper-zinc superoxide dismutase activity in red blood cells and serum in demented patients and in aging. J. Neurol. Sci. 1993, 115:18-25.
27. Dezor M., Dorszewska J., Florczak J., Kempisty D., Jaroszewska-Kolecka J., Rozycka A., et al. Expression of 8-oxoguanine DNA glycosylase 1 (OGG1) and the level of p53 and TNF-alpha proteins in peripheral lymphocytes of patients with Alzheimer's disease. Folia Neuropathol. 2011, 49:123-131.
28. DiDomenico F., Coccia R., Butterfield D., Perluigi M. Circulating biomarkers of protein oxidation for Alzheimer's disease: expectations within limits. Biochim. Biophys. Acta 2011, 1814:1785-1795.
29. Dildar K., Sinem F., Gokhan E., Orhan Y., Filiz M. Serum nitrosative stress levels are increased in Alzheimer disease but not in vascular dementia. Alzheimer Dis. Assoc. Disord. 2010, 24:194-197.
30. Dixit A., Lakshmi V., Chouhan S., Vaney N. Alteration in oxidative stress markers in blood of patients with dementia. Indian J. Med. Spec. 2011, 1:26-29.
31. Dorszewska J., Florczak J., Rozycka A., Jaroszewska-Kolecka J., Trzeciak W.H., Kozubski W. Polymorphisms of the CHRNA4 gene encoding the alpha4 subunit of nicotinic acetylcholine receptor as related to the oxidative DNA damage and the level of apoptotic proteins in lymphocytes of the patients with Alzheimer's disease. DNA Cell Biol. 2005, 24:786-794.
32. Dorszewska J., Kempisty B., Jaroszewska-Kolecka J., Rozycka A., Florczak J., Lianeri M., et al. Expression and polymorphisms of gene 8-oxoguanine glycosylase 1 and the level of oxidative DNA damage in peripheral blood lymphocytes of patients with Alzheimer's disease. DNA Cell Biol. 2009, 28:579-588.
33. Elovaara I., Palo J., Erkinjunthi T., Sulkava R. Serum and cerebrospinal fluid proteins and the blood brain barrier in Alzheimer's disease and multi-infarct dementia. Eur. Neurol. 1987, 26:229-234.
34. Famulari A.L., Marschoff E., Llesuy S., Kohan S., Serra J., Dominguez R., et al. The antioxidant enzymatic blood profile in Alzheimer's and vascular diseases. Their association and a possible assay to differentiate demented subjects and controls. J. Neurol. Sci. 1996, 141:69-78.
35. Fernandes M.A., Proenca M., Nogueira A.J., Grazina M., Oliveira L., Fernandes A., et al. Influence of apolipoprotein E genotype on blood redox status of Alzheimer's disease patients. Int. J. Mol. Med. 1999, 4:179-186.
36. Foy C., Passmore A., Vahidassr M., Young I., Lawson J. Plasma chain-breaking antioxidants in Alzheimer's disease, vascular dementia and Parkinson's disease. QJM 1999, 92:39-45.
37. Galbusera C., Facheris M., Magni F., Galimberti G., Sala G., Tremolada L., et al. Increased susceptibility to plasma lipid peroxidation in Alzheimer's disease patients. Curr. Alzheimer Res. 2004, 1:103-109.
38. Gerhardsson L., Lundh T., Minthon L., Londos E. Metal concentrations in plasma and cerebrospinal fluid in patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2008, 25:508-515.
39. Giometto B., Argentiero V., Sanson F., Ongaro G., Tavolato B. Acute-phase proteins in Alzheimer's disease. Eur. Neurol. 1988, 28:30-33.
40. Gironi M., Bianchi A., Russo A., et al. Oxidative imbalance in different neurodegenerative diseases with memory impairment. Neurodegener. Dis. 2010, 8:129-137.
41. Glaso M., Nordbo G., Diep L., Bohmer T. Reduced concentrations of several vitamins in normal weight patients with late-onset dementia of the Alzheimer type without vascular disease. J. Nutr. Health Aging 2004, 8:407-413.
42. Gonzalez C., Martin T., Cacho J., Brenas M., Arroyo T., Garcia Berrocal B., et al. Serum zinc copper insulin and lipids in Alzheimer's disease epsilon 4 apolipoprotein E allele carriers. Eur. J. Clin. Invest. 1999, 29:637-642.
43. Guidi I., Galimberti D., Lonati S., Novembrino C., Bamonti F., Tiriticco M., et al. Oxidative imbalance in patients with mild cognitive impairment and Alzheimer's disease. Neurobiol. Aging 2006, 27:262-269.
44. Gutzmann H., Kuhl K.P., Hadler D., Rapp M.A. Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study. Pharmacopsychiatry 2002, 35:12-18.
45. Haines A., Iliffe S., Morgan P., Dormandy T., Wood B. Serum aluminium and zinc and other variables in patients with and without cognitive impairment in the community. Clin. Chim. Acta 1991, 198:261-266.
46. Harrison F.E., Allard J., Bixler R., et al. Antioxidants and cognitive training interact to affect oxidative stress and memory in APP/PSEN1 mice. Nutr. Neurosci. 2009, 12:203-218.
47. Helmer C., Peuchant E., Letenneur L., Bourdel-Marchasson I., Larrieu S., Dartiques J., et al. Association between antioxidant nutritional indicators and the incidence of dementia: results from the PAQUID prospective cohort study. Eur. J. Clin. Nutr. 2003, 57:1555-1561.
48. Huang H.Y., Appel L.J. Supplementation of diets with alpha-tocopherol reduces serum concentrations of gamma- and delta- tocopherol in humans. J. Nutr. 2003, 133:3137-3140.
49. Ihara Y., Hayabara T., Saski K., Fujisawa Y., Wakada R., Yamamoto T., et al. Free radical and superoxide dismutase in blood of patients with Alzheimer's disease and vascular dementia. J. Neurol. Sci. 1997, 153:76-81.
50. Irizarry M.C., Raman R., Schwarzschild M.A., et al. Plasma urate and progression of mild cognitive impairment. Neurodegener. Dis. 2009, 6:23-28.
51. Iuliano L., Monticolo R., Straface F., Spoletini I., Gianni W., Caltagirone C., et al. Vitamin E and enzymatic/oxidative stress-driven oxysterols in amnestic mild cognitive impairment subtypes and Alzheimer's disease. J. Alzheimers Dis. 2010, 21:1383-1392.
52. Jeandel C., Nicolas M.B., Dubois F., Nabet-Belleville F., Penin F., Cuny G. Lipid peroxidation and free radical scavengers in Alzheimer's disease. Gerontology 1989, 35:275-282.
53. Jimenez-Jimenez F.J., de Bustos F., Molina J., Benito-Leon J., Tallon-Barranco A., Gasalla T., et al. Cerebrospinal fluid levels of alpha-tocopherol (vitamin E) in Alzheimer's disease. J. Neural Transm. 1997, 104:703-710.
54. Kaikkonen J., Kosonen L., Nyyssonen K., et al. Effect of combined coenzyme Q10 and d-alpha-tocopheryl acetate supplementation on exercise-induced lipid peroxidation and muscular damage: a placebo-controlled double-blind study in marathon runners. Free Radic. Res. 1998, 29:85-92.
55. Kalman J., Dey I., Llona S., Matkovics B., Brown D., Janka Z., et al. Plate membrane fluidity and plasma malondialdehyde in Alzheimer's dementia patients with and without family history of dementia. Biol. Psychiatry 1994, 35:190-194.
56. Kalman J., Kudchodkar B., Marray K., McConathy W., Juhasz A., Janka Z., Lacko A. Evaluation of serum-lipid-related cardiovascular risk factors in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 1999, 10:488-493.
57. Kapaki E., Segditsa J., Papageorgiou C. Zinc copper and magnesium concentration in serum and CSF of patients with neurological disorders. Acta Neurol. Scand. 1989, 79:373-378.
58. Kassner S.S., Bonaterra G.A., Kaiser E., Hildebrandt W., Metz J., Schroder J., Kinscherf R. Novel systemic markers for patients with Alzheimer disease? - A pilot study. Curr. Alzheimer Res. 2008, 5:358-366.
59. Kharrazi H., Vaisi-Raygani A., Rahimi Z., Tavilani H., Aminian M., Pourmotabbed T. Association between enzymatic and non-enzymatic antioxidant defense mechanism with apolipoproetin E genotypes in Alzheimer Disease. Clin. Biochem. 2008, 41:932-936.
60. Kim T.S., Pae C.U., Yoon S., Jang W., Lee N., Kim J., et al. Decreased plasma antioxidants in patients with Alzheimer's disease. Int. J. Geriatr. Psychopharmacol. 2006, 21:344-348.
61. Laske C., Leyhe T., Stransky E., Hoffmann N., Fallgatter A.J., Dietzsch J. Identification of a blood-based biomarker panel for classification of Alzheimer's disease. Int. J. Neuropsychopharmacol. 2011, 14:1147-1155.
62. Li C., Ford E.S., Zhao G., Balluz L.S., Giles W.H., Liu S. Serum alpha-carotene concentrations and risk of death among US adults: the Third National Health and Nutrition Examination Survey follow-up study. Arch. Intern. Med. 2011, 171:507-515.
63. Licastro F., Morini M.C., Polazzi E., Davis L.J. Increased serum alpha 1 antichemotrypsin in patients with probable Alzheimer's disease: an acute phase reactant without the peripheral acute phase response. J. Neuroimmunol. 1995, 57:71-75.
64. Licastro F., Davis L.J., Polazzi E., Rossi S., Cucinotta D. Serological alpha 1 antichymotrypsin in patients with probable senile dementia of Alzheimer type: a short-term longitudinal trial. Alzheimer Dis. Assoc. Disord. 1996, 10:192-196.
65. Maesaka J., Wolf-Klein G., Piccione J., Ma C. Hypouricemia, abnormal renal tubular urate transport and plasma natriuretic factors in patients with Alzheimer's disease. J. Am. Geriatr. Soc. 1993, 41:501-506.
66. Maiorino M., Zamburlini A., Roveri A., Ursini F. Prooxidant role of vitamin E in copper induced lipid oxidation. FEBS Lett. 1993, 330:174-176.
67. Martin-Aragon S., Bermejo-Bescos P., Benedi J., et al. Metalloproteinase's activity and oxidative stress in mild cognitive impairment and Alzheimer's disease. Neurochem. Res. 2009, 34:373-378.
68. McDonald S.R., Sohal R.S., Forster M.J. Concurrent administration of co-enzyme Q10 and alpha-tocopherol improves learning in aged mice. Free Radic. Biol. Med. 2005, 38:729-736.
69. McGrath L., McGleenon B., Brennan S., McDoll D., McIlroy S., Passmore A. Increased oxidative stress in Alzheimer's disease as assessed with 4-hydroxynonenal but not malondialdehyde. QJM 1998, 94:485-490. (Mecocci).
70. Meccoci P., Polidori M.C. Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease. Biochem. Biophys. Acta 2012, 1822:631-638.
71. Mecocci P., Polidori M., Ingegni T., Cherubini A., Chionne F., Cecchetti R., Senin U. Oxidative damage to DNA in Lymphocytes from AD patients. Neurology 1998, 51:1014-1017.
72. Mecocci P., Polidori M., Cherubini A., Ingegni T., Mattioli P., Catani M., et al. Lymphocyte oxidative DNA damage and plasma antioxidants in Alzheimer's disease. Arch. Neurol. 2002, 59:794-798.
73. Migliore L., Fontana I., Trippi F., et al. Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients. Neurobiol. Aging 2005, 26:567-573.
74. Milward E.A., Bruce D.G., Knuiman M.W., et al. A cross-sectional community study of serum iron measures and cognitive status in older adults. J. Alzheimers Dis. 2010, 20:617-623.
75. Molaschi M., Ponzetto M., Bertacna E., Farrario E. Determination of selected trace elements in patients affected by dementia. Arch Gerontol. Geriatr. 1996, 22(Suppl. 1):39-42.
76. Molina J., Jimenez-Jimenez F., Aguilar M., Meseguer I., Mateos-Vega C., Gonzalez-Munoz M., et al. Cerebrospinal fluid levels of transition metals in patients with Alzheimer's disease. J. Neural Transm. 1998, 105:479-488.
77. Morris M.C., Evans D.A., Tangney C.C., et al. Dietary copper and high saturated and trans fat intakes associated with cognitive decline. Arch. Neurol. 2006, 63:1085-1088.
78. Mueller C., Schrag M., Crofton A., Muckenthaler M.U., Magaki S., Kirsch W.M. Circulating markers of iron and copper dyshomeostasis in Alzheimer's disease and mild cognitive impairment. J. Alzheimers Dis. 2012, 29:341-350.
79. Mulholland C.W., Strain J.J. Total radical-trapping antioxidant potential (TRAP) of plasma: effects of supplementation of young healthy volunteers with large doses of alpha-tocopherol and ascorbic acid. Int. J. Vitam. Nutr. Res. 1993, 63:27-30.
80. Nunomura A., Tamaoki T., Motohashi N., et al. The earliest stage of cognitive impairment in transition from normal aging to Alzheimer disease is marked by prominent RNA oxidation in vulnerable neurons. J. Neuropathol. Exp. Neurol. 2012, 71:233-241.
81. Ozcankaya R., Delibas N. Malondialdehyde, superoxide dismutase, melatonin, iron, copper, and zinc blood concentrations in patients with Alzheimer's disease: cross-sectional study. Croat. Med. J. 2002, 43:28-32.
82. Padurariu M., Ciobica A., Hritcu L., Stoica B., Bild W., Stefanescu C. Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer's disease. Neurosci. Lett. 2010, 469:6-10.
83. Paraskevas G., Kapaki E., Libitaki G., Zournas C., Segditsa I., Papgeoriou C. Ascorbate in healthy subjects, amyotrophic lateral sclerosis and Alzheimer's disease. Acta Neurol. Scand. 1997, 96:88-90.
84. Pascoal A. Study of iron and copper metabolism in Alzheimer's disease 2009, (Graduate thesis), Repository of the University of Lisboa.
85. Perrin R., Briancon S., Jeandel C., Artur Y., Minn A., Penin F., Siest G. Blood activity of Cu/Zn superoxide dismutase, glutathione peroxidase and catalase in Alzheimer's disease: a case-control study. Gerontology 1990, 36:306-313.
86. Peterson R.C., Thomas R.G., Grundman M., et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med. 2005, 352:2379-2388.
87. Polidori M.C., Mecocci P. Plasma susceptibility to free radical-induced antioxidant consumption and lipid peroxidation is increased in very old subjects with Alzheimer's disease. J. Alzheimers Dis. 2002, 4:517-522.
88. Polidori M.C., Mattioli P., Aldred S., Cecchetti R., Stahl W., Griffiths H., et al. Plasma antioxidant status, immunoglobulin g oxidation and lipid peroxidation in demented patients: relevance to Alzheimer disease and vascular dementia. Dement. Geriatr. Cogn. Disord. 2004, 18:265-270.
89. Porkkala-Sarataho E., Salonen J.T., Nyyssonen K., et al. Long-term effects of vitamin E, vitamin C, and combined supplementation on urinary 7-hydro-8-oxo-2'-deoxyguanosine, serum cholesterol oxidation products and oxidation resistance of lipids in nondepleted men. Arterioscler. Thromb. Vasc. Biol. 2000, 20:2087-2093.
90. Puertas M., Martinez-Martinez J., Cobo M., Carrera M.P., Mayas M., Ramirez-Exposito M. Plasma oxidative stress parameters in men and women with early stage Alzheimer type dementia. Exp. Gerontol. 2012, 47:625-630.
91. Pulido R., Jimenez-Escrig A., Orensanz L., Saura-Calixto F., Jimenez-Escrig A. Study of plasma antioxidant status in Alzheimer's disease. Eur. Neurol. 2005, 12:531-535.
92. Repetto M.G., Reides C., Evelson P., Kohan S., de Lustig E., Llesuy S. Peripheral markers of oxidative stress in probable Alzheimer patients. Eur. J. Clin. Invest. 1999, 29:643-649.
93. Rinaldi P., Polidori M.C., Metastasia A., Mariani E., Mattioli P., Cherubini A., et al. Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol. Aging 2003, 24:915-919.
94. Riviere S., Birlouez-Aragon I., Nourhashemi R., Vellas B. Low plasma vitamin C in Alzheimer's patients despite an adequate diet. Int. J. Geriatr. Psychopharmacol. 1998, 13:749-754.
95. Rossi L., Squitti R., Pasqualetti P., Marchese E., Cassetta E., Forastiere E., et al. Red blood cell copper, zinc superoxide dismutase activity is higher in Alzheimer's disease and is decreased by d-penicillamine. Neurosci. Lett. 2002, 329:137-140.
96. Sano M., Ernesto C., Thomas R.G., et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N. Engl. J. Med. 1997, 336:1216-1222.
97. Schippling S., Kontush A., Arlt S., Buhmann C., Sturenburg H., Mann U., et al. Increased lipoprotein oxidation in Alzheimer's disease. Free Radic. Biol. Med. 2000, 28:351-360.
98. Schrag M., Mueller C., Oyoyo U., Smith M.A., Kirsch W. Iron, zinc and copper in the Alzheimer's disease brain: a quantitative meta-analysis. Some insight on the influence of citation bias on scientific opinion. Prog. Neurobiol. 2011, 94:296-306.
99. Sedighi B., Shafa M., Shariati M. A study of serum copper and ceruloplasmin in Alzheimer's disease in Kerman Iran. Asia Neurol. 2006, 11:107-109.
100. Sekler A., Jimenez J., Rojo L., Pastene E., Fuentes P., Slachevsky A., Maccioni R.B. Cognitive impairment and Alzheimer's disease: links with oxidative stress and cholesterol metabolism. Neuropsychiatr. Dis. Treat. 2008, 4:715-722.
101. Serra J.A., Famulari A., Kohan S., Marschoff E.R., Dominguez R.O., de Lustig E.S. Copper-zinc superoxide dismutase activity in red blood cells in probable Alzheimer's disease. J. Neurol. Sci. 1994, 122:179-188.
102. Serra J.A., Marschoff E., Dominguez R.O., de Lustig E.S., Famulari A., Bartolome E.L., Guareschi E.M. Comparison of the determination of superoxide dismutase and antioxidant capacity in neurological patients using two different procedures. Clin. Chim. Acta 2000, 301:87-102.
103. Serra J., Dominguez R., de Lustig E.S., Guareschi E.M., Famulari A., Bartolome A., Marschoff E. Parkinson's disease is associated with oxidative stress: comparison of peripheral antioxidant profiles in living Parkinson's, Alzheimer's and vascular dementia patients. J. Neurol. Transm. 2001, 108:1135-1148.
104. Serra J.A., Marschoff E.R., Dominguez R.O., Guareschi E.M., Famulari A.L., Pagano M.A., et al. Oxidative stress in Alzheimer's and vascular dementias: masking of the antioxidant profiles by a concomitant Type II diabetes mellitus condition. J. Neurol. Sci. 2004, 218:17-24.
105. Serra J.A., Dominguez R., Marschoff E.R., Guareschi E., Famulari E., Boveris A. Systemic oxidative stress associated with the neurological disease of aging. Neurochem. Res. 2009, 34:2122-2123.
106. Sevim S., Oxgur U., Tamer L., Dogu O., Ozge A. Can serum levels of copper and zinc distinguish Alzheimer's patients from normal subjects. J. Neurol. Sci. 2007, 24:197-205.
107. Shardell M.D., Alley D.E., Hicks G.E., et al. Low-serum carotenoid concentrations and carotenoid interactions predict mortality in US adults: the Third National Health and Nutrition Examination Survey. Nutr. Res. 2011, 31:178-189.
108. Shore D., Henkin R., Nelson N., Agarwal R., Wyatt R. Hair and serum copper, zinc, calcium and magnesium concentrations in Alzheimer-type dementia. J. Am. Geriatr. Soc. 1984, 32:892-895.
109. Sinclair A., Bayer A., Johnston J., Warner C., Maxwell S. Altered plasma antioxidant status in subjects with Alzheimer's disease and vascular dementia. Int. J. Geriatr. Psychiatry 1998, 13:840-845.
110. Sinem F., Dildar K., Gokhan E., Melda B., Orhan Y., Filiz M. The serum protein and lipid oxidation marker levels in Alzheimer's disease and effects of cholinesterase inhibitors and antipsychotic drugs therapy. Curr. Alzheimers Res. 2010, 7:463-469.
111. Snaedal J., Kristinsson J., Gunnarsdottir S., Olafsdottir A., Baldvinsson M., Johannesson T. Copper, ceruloplasmin and superoxide dismutase in patients with Alzheimer's disease: a case-control study. Dement. Cogn. Geriatr. Dis 1998, 9:239-242.
112. Squitti R. Metals in Alzheimer's disease: a systematic perspective. Front. Biosci. 2012, 17:451-472.
113. Squitti R., Lupoi D., Pasqualetti P., Dal Forno G., Vernieri F., Chiovenda P., et al. Elevation of serum copper levels in Alzheimer's disease. Neurology 2002, 59:1153-1161.
114. Squitti R., Pasqualetti P., Dal Forno G., Moffa F., Cassetta E., Lupoi D., et al. Excess of serum copper not related to ceruloplasmin in Alzheimer's disease. Neurology 2005, 64:1040-1046.
115. Squitti R., Barbati G., Rossi L., et al. Excess of non-ceruloplasmin serum copper in AD correlates with MMSE, CSF β-amyloid and h-tau. Neurology 2006, 67:76-82.
116. Squitti R., Quattrocchi C., Forno G.D., Antuono P., Wekstein D., Capo C., et al. Ceruloplasmin pattern and copper content in serum and brain of Alzheimer's disease patients. Biomark. Insights 2007, 1:205-213.
117. Squitti R., Bressi F., Pasqualetti P., Bonomini C., Ghidoni R., Binetti G., et al. Longitudinal prognostic value of serum "free" copper in patients with Alzheimer disease. Neurology 2009, 72:50-55.
118. Squitti R., Salustri C., Siotto M., Ventriglia M., Vernieri F., Lupoi D., et al. Ceruloplasmin/transferrin ratio changes in Alzheimer's disease. Int. J. Alzheimers Dis. 2010, 2011:231595.
119. Squitti R., Ghidoni R., Scrascia F., Benussi L., Panetta V., Pascualetti P., et al. Free copper distinguishes mild cognitive impairment from healthy elderly individuals. J. Alzheimers Dis. 2011, 23:239-248.
120. Squitti R., Polimanti R., Bucossi S., Ventriglia M., Mariani S., Manfellotto D., et al. Linkage disequilibrium and haplotype analysis of the ATP7B gene in Alzheimer's disease. Rejuvenation Res. 2013, 16:3-10.
121. Stahl W., Sies H. Antioxidant activity of carotenoids. Mol. Asp. Med. 2003, 24:345-351.
122. Sultana R., Mecocci P., Mangialasche F., Cecchetti R., Boglioni M., Butterfield D.A. Increased protein and lipid oxidative damage in mitochondria isolated from lymphocytes from patients with Alzheimer's disease: insights into the role of oxidative stress in Alzheimer's disease and initial investigations into a potential biomarker for this dementing disorder. J. Alzheimers Dis. 2011, 24:77-84.
123. Tabet N., Mantle D., Walker Z., Orell M. Vitamins, trace elements, and antioxidant status in dementia disorders. Int. Psychogeriatr. 2001, 13:265-275.
124. Tabet N., Walker Z., Mantle D., Costa D., Orrell M. In vivo dopamine pre-synaptic receptors and antioxidant activities in patients with Alzheimer's disease, dementia with Lewy bodies and in controls. A preliminary report. Dement. Geriatr. Cogn. Dis. 2003, 16:46-51.
125. Torres L.L., Quaglio N.B., de Souza G.T., et al. Peripheral oxidative stress biomarkers in mild cognitive impairment and Alzheimer's disease. J. Alzheimer's Dis. 2011, 26:59-68.
126. Torsdottir G., Kristinsson J., Snaedal J., Johannesson T. Ceruloplasmin and iron proteins in the serum of patients with Alzheimer's disease. Dement. Geriatr. Cogn. Dis. Extra 2011, 1:366-371.
127. Von Arnim C., Herbolsheimer F., Nikolaus T., Peter R., Biesalski H., Ludolph A., Riepe M., Nagel G. Diet antioxidants and dementia in a population-based case-control study among older people in south Germany. J. Alzheimers Dis. 2012, 31:717-724.
128. Vural H., Demirin H., Kara Y., Eren I., Delibas N. Alterations of plasma magnesium, copper, zinc, iron and selenium concentrations and some related erythrocyte antioxidant enzyme activities in patients with Alzheimer's disease. J. Trace Elem. Med. Biol. 2010, 24:169-173.
129. Wayner D.D., Burton G.W., Ingold K.U., Locke S. Quantitative measurement of total peroxyl radical-trapping antioxidant capability of human blood plasma by controlled peroxidation. The important contribution made by plasma proteins. FEBS Lett. 1985, 187:33-37.
130. Wayner D.D., Burton G.W., Ingold K.U., Barclay L.R., Locke S.J. The relative contributions of vitamin E, urate, ascorbate and proteins to the total peroxyl radical-trapping antioxidant activity of human blood plasma. Biochim. Biophys. Acta 1987, 924:408-419.
131. Yamada K., Tanaka T., Han D., Senzaki K., Kameyama T., Nabeshima T. Protective effects of idebenone and alpha-tocopherol on beta-amyloid (1-42) induced learning and memory deficits in rats: implication of oxidative stress in beta-amyloid-induced neurotoxicity in vivo. Eur. J. Neurosci. 1999, 11:83-90.
132. Zafrilla P., Mulero J., Xandri J.M., Santo E., Caravaca G., Morillas J.M. Oxidative stress in Alzheimer patients in different stages of the disease. Curr. Med. Chem. 2006, 13:1075-1083.
133. Zaman Z., Roche S., Fielden P., Frost P.G., Niriella D.C., Cayley A.C. Plasma concentrations of vitamins A and E and carotenoids in Alzheimer's disease. Age Aging 1992, 21:91-94.
134. Zappasodi F., Salustri C., Babiloni C., Cassetta E., Del Percio C., Ercolani M., et al. An observational study on the influence of the APOE-epsilon4 allele on the correlation between 'free' copper toxicosis and EEG activity in Alzheimer disease. Brain Res. 2008, 1215:183-189.